Key issues in inhibitor management in patients with haemophilia.
作者信息
Gomez Keith, Klamroth Robert, Mahlangu Johnny, Mancuso Maria E, Mingot María E, Ozelo Margareth Castro
机构信息
Katherine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom.
Department for Internal Medicine, Haemophilia Treatment Centre Vivantes, Klinikum im Friedrichshain, Berlin, Germany.
出版信息
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s319-29. doi: 10.2450/2013.0246-12. Epub 2013 Dec 3.
Abstract
摘要
相似文献
1
Key issues in inhibitor management in patients with haemophilia.
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s319-29. doi: 10.2450/2013.0246-12. Epub 2013 Dec 3.
2
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15.
3
Switching haemophilia products and inhibitor risk: a United States' perspective.
Eur J Haematol. 2015 Apr;94(4):283. doi: 10.1111/ejh.12441.
4
Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Thromb Haemost. 1999 Aug;82(2):531-9.
5
Inhibitors - cellular aspects and novel approaches for tolerance.
Haemophilia. 2014 May;20 Suppl 4(0 4):80-6. doi: 10.1111/hae.12407.
6
Management of factor VIII inhibitors: evolution and current status.
Haemostasis. 1992;22(5):268-75. doi: 10.1159/000216334.
7
How I manage patients with inherited haemophilia A and B and factor inhibitors.
Br J Haematol. 2018 Feb;180(4):501-510. doi: 10.1111/bjh.15053. Epub 2017 Dec 22.
8
Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
Thromb Haemost. 1995 Mar;73(3):553-5.
9
A therapeutic alternative for haemophiliacs with inhibitors.
Acta Paediatr. 1992 Jun-Jul;81(6-7):564-5. doi: 10.1111/j.1651-2227.1992.tb12297.x.
10
The molecular basis of haemophilia A and B.
Baillieres Clin Haematol. 1996 Jun;9(2):211-28. doi: 10.1016/s0950-3536(96)80059-x.
引用本文的文献
1
Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset.
J Blood Med. 2024 Apr 24;15:191-205. doi: 10.2147/JBM.S443380. eCollection 2024.
2
Surgical Emergencies in Patients with Hemophilia A-What to Expect.
Healthcare (Basel). 2024 Mar 7;12(6):610. doi: 10.3390/healthcare12060610.
3
Successful transfemoral prosthesis in a patient with haemophilia A and factor VIII inhibitors: A case report.
J Int Med Res. 2023 Aug;51(8):3000605231195446. doi: 10.1177/03000605231195446.
4
The Impact of Recombinant Versus Plasma-Derived Factor VIII Concentrates on Inhibitor Development in Previously Untreated Patients With Hemophilia A: A 2021 Update of a Systematic Review and Meta-Analysis.
Cureus. 2022 Jun 16;14(6):e26015. doi: 10.7759/cureus.26015. eCollection 2022 Jun.
5
Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study.
Ther Adv Hematol. 2021 Apr 30;12:20406207211007058. doi: 10.1177/20406207211007058. eCollection 2021.
6
Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients.
Adv Hematol. 2020 Sep 9;2020:8768074. doi: 10.1155/2020/8768074. eCollection 2020.
7
Molecular Mechanisms of Inhibitor Development in Hemophilia.
Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020001. doi: 10.4084/MJHID.2020.001. eCollection 2020.
8
Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.
Blood Adv. 2019 May 14;3(9):1368-1378. doi: 10.1182/bloodadvances.2017007914.
9
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.
Haemophilia. 2019 Jul;25(4):676-684. doi: 10.1111/hae.13762. Epub 2019 Apr 29.
10
The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.
Ther Adv Hematol. 2018 Oct 10;9(10):319-334. doi: 10.1177/2040620718799997. eCollection 2018 Oct.
本文引用的文献
1
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
Blood. 2013 May 16;121(20):4046-55. doi: 10.1182/blood-2012-09-457036. Epub 2013 Apr 3.
2
The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia.
Br J Haematol. 2013 May;161(3):424-33. doi: 10.1111/bjh.12267. Epub 2013 Feb 22.
3
Inhibitors: our greatest challenge. Can we minimize the incidence?
Haemophilia. 2013 Jan;19 Suppl 1:2-7. doi: 10.1111/hae.12049.
4
PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.
Thromb Res. 2012 Dec;130(6):864-70. doi: 10.1016/j.thromres.2012.08.305. Epub 2012 Sep 8.
5
Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
Haemophilia. 2012 Nov;18(6):990-6. doi: 10.1111/j.1365-2516.2012.02864.x. Epub 2012 May 28.
6
Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
Haemophilia. 2012 Sep;18(5):798-804. doi: 10.1111/j.1365-2516.2012.02789.x. Epub 2012 Apr 19.
7
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
J Thromb Haemost. 2012 Jan;10(1):81-9. doi: 10.1111/j.1538-7836.2011.04549.x.
8
Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.
J Thromb Haemost. 2012 May;10(5):773-80. doi: 10.1111/j.1538-7836.2012.04667.x.
9
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.
Blood. 2012 Mar 22;119(12):2922-34. doi: 10.1182/blood-2011-09-379453. Epub 2012 Jan 26.
10
The principal results of the International Immune Tolerance Study: a randomized dose comparison.
Blood. 2012 Feb 9;119(6):1335-44. doi: 10.1182/blood-2011-08-369132. Epub 2011 Nov 18.
Zotero 插件